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Background: The IDEAL (Idea, Development, Evaluation, Assessment, Long-term study) framework
is a scheme of investigation for innovative surgical therapeutic interventions. Pressurized intraperitoneal
aerosol chemotherapy (PIPAC) is a procedure based on laparoscopy to deliver intraperitoneal chemother-
apy for peritoneal metastases, introduced in 2011. The aim of this article was to review literature on
PIPAC and assess whether development of the technique has followed the IDEAL framework.
Methods: A search of MEDLINE and Embase was carried out to identify scientific reports on PIPAC
published between January 2000 and February 2019. The studies were categorized according to the
IDEAL stages.
Results: Eighty-six original research papers on PIPAC were identified. There were 23 stage 0, 18 stage
1, 25 stage 2a and six stage 2b studies. Protocol papers for stage 1, 2b and 3 studies, and trial registrations
for stage 2a studies, were also identified. The number of centres publishing reports and the number of
publications has increased each year. Overall, there has been progression through the IDEAL stages;
however, about 60 per cent of clinical reports published in 2018 were stage 1 Idea-type studies.
Conclusion: Since its introduction, studies investigating PIPAC have progressed in line with the IDEAL
framework. However, the majority of studies reported recently were stage 0 and 1 studies.
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Introduction
In 2008, the Society of University Surgeons defined an
innovative procedure as one that ‘differs from currently
accepted local practice, the outcomes of which have not
been described, and which may entail risk to the patient’1.
The IDEAL (Idea, Development, Evaluation, Assessment,
Long-term study) framework is a scheme of investigation
for innovative surgical therapeutic interventions proposed
by the Balliol Collaboration in 20092–5 as a strategy to
address concerns regarding shortcomings of research in
surgery, with particular reference to novel procedures and
practices (Table 1). The framework requires that surgical
innovation should be carried out in a coordinated manner,
with investigations progressing to a series of randomized
trials. The results of the process should be audited using a
clinical registry.
Pressurized intraperitoneal aerosol chemotherapy
(PIPAC) for peritoneal metastases is a laparoscopic proce-
dure used to assess the burden of the peritoneal disease,
take biopsies, and deliver intraperitoneal chemotherapy
as an aerosol, without increasing the intra-abdominal
pressure6. Intraperitoneal administration of chemother-
apy for peritoneal metastases from ovarian cancer was
developed in the 1970s7 and has subsequently been
used for many different cancer types in the context of
heated intraperitoneal chemotherapy (HIPEC) and early
postoperative intraperitoneal chemotherapy (EPIC)8.
Experimental work9–11 suggests that both increased
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Table 1 Summary of the stages of surgical innovation according to the IDEAL paradigm (adapted from references 2 and 5), with
description of the interpretation of these stages in this review relating to published work on pressurized intraperitoneal aerosol
chemotherapy
Stage of
innovation Description
No. of
patients
Proposed method
of investigation Studies in this stage included in this review
0 – Idea Preclinical work in vitro and in animals None Varied Preclinical studies in animals (in vivo and
post-mortem models) and in vitro
1 – Idea First human applications: proof of
concept and small safety studies
Very few Structured case
reports
Case reports and small case series.
Occupational health and safety studies.
Scientific studies of clinical samples
Data presented relate to safety and/or initial
feasibility/proof of concept
Prospective or retrospective data collection
2a – Development Major technical details defined but
technique remains experimental
Few, selected Prospective
development studies
Larger case series, and single-arm
non-randomized studies. Scientific studies
of clinical samples
Prospective or retrospective data collection
2b – Exploration Individual learning curves progressing
quickly, with resulting increase in
patient accrual and broadening of
indication. Effectiveness still not
demonstrated formally
Many, mixed Research database,
explanatory or
feasibility RCT
Large case series from a prospectively
maintained database, and RCTs. Scientific
studies of clinical samples. Prospective
study relating to a new indication for the
technique
Primary outcomes are efficacy-related.
Prospective data collection
3 – Assessment Procedure is part of many surgeons’
practice and becoming the
standard of care
Many, variable RCT RCT with primary outcome relating to efficacy
4 – Long-term Procedure is routine practice and
long-term outcomes and late/rare
complications can be monitored
Almost all Registry, rare case
reports
Not applicable
temperature and increased pressure can enhance the
effect of chemotherapy. The concept of PIPAC was first
described in 200012, and was first performed in a patient
in 201113.
The aim of this literature review was to assess whether
the development and introduction of PIPAC has followed
the IDEAL framework.
Methods
A literature search of the Ovid database was carried
out using the terms ‘PIPAC’, ‘ePIPAC’, ‘aerosol$ adj3
chemotherapy’ and ‘pressuri$ adj3 chemotherapy’ on 28
February 2019. The first report describing the concept of
a ‘therapeutic capnoperitoneum’ was published in 200012,
so the search was limited from 1 January 2000 to February
2019. In addition, the reference lists of identified papers
were screened, and ResearchGate.net was searched for the
term PIPAC to identify other publications.
Conference abstracts, review articles, articles associated
with videos, and book chapters were excluded, as were
errata to articles. Only articles in English were reviewed.
The full text was then obtained, and the studies were
graded according to the stages of innovation set out in
the IDEAL paradigm. To obtain an up-to-date picture of
research activity, ClinicalTrials.gov and the EU Clinical
Trials Register (EudraCT) were searched to identify trials.
The results were cross-referenced with the identified
publications. Trials that had not yet been reported in the
literature were included and assigned a stage as published
protocols. Criteria used to assign the stages are described
in Table 1.
Results
PIPAC: a review of the literature in stages
The search strategy identified 287 articles after duplicates
were removed (Fig. 1). Some 172 articles were excluded
after review of the title and abstract, and a further 29 were
excluded after reviewing the full text. This left 81 original
research papers on PIPAC and/or related technology, and
five trial registrations.
Overall, the search identified: 23 stage 0 studies6,12,14–34;
18 stage 1 studies13,35–51 and two protocol papers52,53
for stage 1 studies; 25 stage 2a studies54–78, one protocol
paper79 and five trial registrations (NCT01854255,
NCT02735928, NCT03246321, NCT02604784 and
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Fig. 1 Flow diagram of the literature search and selection of articles for review
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Additional records identified through other
 sources n= 13
Trial registrations identified on
 ClinicalTrials.gov and EudraCT n= 23
Records screened for title
and abstract after
duplicates removed
n= 287 Records excluded n= 172
 Not a study of PIPAC or related
  science n= 127
 PIPAC article not in English n= 10
 Erratum n= 2
 Conference abstract n= 33
Full-text articles assessed
for eligibility
n= 115
Full-text articles excluded n= 29
 Multiple publications or sources
  (e.g. trial registration and published
  results) n= 14
 Review article or editorial n= 13
 Publication associated with video n= 2
Studies included in the review n= 86
 Stage 0: 23
 Stage 1: 18 and 2 published protocols
 Stage 2a: 25, 1 published protocol and
 5 trial registrations
 Stage 2b: 6 and 3 published protocols
 Stage 3: 3 published protocols
Search of the EU Clinical Trials Register (EudraCT) and the USNational Library of Medicine Trials Register (ClinicalTrials.gov) is also included. PIPAC,
pressurized intraperitoneal aerosol chemotherapy.
NCT03124394) for stage 2a studies; six stage 2b
studies80–85 and three protocol papers86–88 for stage
2b studies; and three protocol papers89–91 for stage 3
studies. Fig. 2 shows the evolution of the literature and
the geographical location of authors publishing in this
field.
The number of publications increased each year, from
five or fewer before 2016, increasing to 17 publications in
2016, 18 in 2017, and 37 in 2018. The cumulative num-
ber of active centres has also increased. In general, there
has been progression through the stages of innovation, with
increasing numbers of Development and Evaluation stud-
ies as time passed.
The proportion of papers classified as either IDEAL
stage 2a, 2b or 3 has increased over time, with 23 of 37
(62 per cent) of reports published in 2018 describing these
types of studies. However, the majority of new centres
began their programme of clinical research with a stage 1
Idea study.
The first publication from 11 of 17 centres (65 per cent)
that reported clinical results described a stage 1 study,
including six of nine centres (67 per cent) that published
their first clinical study in 2018.
Stage 0 – Idea: preclinical work
The potential to deliver drugs by aerosolization into the
pneumoperitoneum at laparoscopy was demonstrated
initially in vivo in a pig model in 200012. Two hypothe-
ses were proposed12 to support the technique. The first
hypothesis was that intraperitoneal chemotherapy was
superior to intravenous chemotherapy for the treatment
of peritoneal metastases. The second was that delivery of
intraperitoneal chemotherapy as an aerosolized solution
to the pressurized pneumoperitoneum would confer phar-
macological advantages over chemotherapy in the liquid
phase, specifically better distribution around the abdominal
cavity and improved penetration into the tissues.
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Fig. 2 Adoption of pressurized intraperitoneal aerosol chemotherapy according to the IDEAL criteria
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Studies were identified using the search strategy described in Fig. 1. Included studies were then reviewed by a single author and assigned a stage of innovation
according to the description of the stage and proposed method of investigation suggested by the IDEAL paradigm, as described in Table 1. Study centres
are described by the city where the institution of the lead author was located. The number of studies published by each centre is shown, broken down by
year and stage of innovation: I, Idea; D, Development; E, Exploration; A, Assessment; P, protocol paper. *Protocol from ClinicalTrials.gov. †Protocol for
multicentre study; other authors are from centres in Lausanne (Switzerland), Odense (Denmark), Paris (France), Tübingen (Germany) and Turin (Italy).
‡Multicentre study; other authors are from centres in Clermont Ferrand andMontpellier (France). §Protocol for multicentre study; other authors are from
centres in Berlin, Bochum, Tübingen andWiesbaden (Germany) and Rome (Italy). ¶Protocol for multicentre study; other authors are from centres in Lyon
and Paris (France). #Protocol for multicentre study; other authors are from centres in Berlin, Bochum, Leipzig, Regensburg and Tübingen (Germany) and
Geneva (Switzerland).
The first studies6,12 investigating the technique used
methylene blue dye, allowing visual assessment of the dis-
tribution and penetration of the aerosol versus lavage in an
in vivo pig model. Distribution of the dye was observed to
be superior for aerosolization, although this was assessed
by visual inspection. The second stage of preclinical testing
involved an ex vivo tissue model to assess the penetration of
a therapeutic substance, Dbait, into peritoneal tissue from
a patient withmetastatic endometrial cancer14. Dbait pene-
tration was assessed using immunohistochemistry. Nodules
treated with a pressurized aerosol had a more homoge-
neous drug uptake and deeper penetration than nodules
treated by lavage.
Following these preclinical experiments, the same team
progressed to human applications. Subsequent preclinical
studies by other groups suggested that the first generation
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of PIPAC technology had limitations. Experiments using
chemotherapeutic agents, where drug uptake can be mea-
sured objectively, found that drug distribution and penetra-
tion in ex vivo18,20 and post-mortem animal21 models was
heterogeneous. Although drug was detected in tissue that
had not been exposed directly to the aerosol jet, the greatest
deposition of the aerosol was opposite to the nebulizer.
Analysis of the aerosol has shown that the droplet size is
heterogeneous23. One group24 has developed and brought
to market a second device to enable PIPAC, but there is
currently little information on the technical performance
of this device, nor on its use outside Brazil.
Stage 1 – Idea: first human applications
The first human applications of PIPAC were carried out
between 2011 and 2013, and the first reports were pub-
lished in 201335 and 201413. PIPAC was delivered as an
off-label therapy to patients for whom ‘no satisfactory alter-
native therapy was available’ as a result of progression on
systemic treatment or intolerance to systemic treatment.
Patients were treated with doxorubicin 1⋅5mg/m2 in 50ml
0⋅9 per cent saline, and cisplatin 7⋅5mg/m2 in 150ml 0⋅9
per cent saline, the doses being set arbitrarily as 10 per cent
of the HIPEC doses used at that institution. A formal dose
escalation study was not done until 201848. The drugs were
administered using the nebulizer device (MicroPump™,
Reger Medizintechnik, Rottweil, Germany, until 2015;
then CapnoPen®, Capnomed, Villingendorf, Germany,
from 2015), and the pneumoperitoneum was then left in
a steady state for 30min. Regressive histological changes
were observed in repeat biopsies from consecutive pro-
cedures, suggesting efficacy. Mild and moderate adverse
events were reported, with patients experiencing fatigue,
fever, pain and vomiting after surgery80. Pharmacokinetic
data were collected; these determined that systemic absorp-
tion of the chemotherapy agents was low, although only
doxorubicin was monitored13.
Data on the occupational health and safety aspects of
the technique were collected, with no evidence of plat-
inum contamination in the operating theatres36,80. As
centres across Europe started performing the procedure,
verification of its occupational health and safety was
repeated41,43–45. Similarly, as shown in Fig. 2, small case
series describing the initial experiences of new centres
have been published40,46,47,49,51.
Stage 2a – Development: larger case series
The PIPAC programme at the original centre in Ruhr
University Bochum, Germany, continued and further case
series were published, including patients with colorectal
cancer78,81, primary peritoneal cancer81, gastric cancer58,81
and malignant mesothelioma81. In gastrointestinal
cancer78, oxaliplatin was used at a dose of 92mg/m2.
Again, this was an arbitrarily derived dose, and no formal
dose-finding study has been published. A larger series of
patients with ovarian cancer included one patient who sus-
tained a life-threatening bowel perforation; however, this
occurred when PIPAC was combined with cytoreductive
surgery74.
A PIPAC training programmewas developed, and sales of
the device required to deliver PIPAC were limited to clini-
cians who had been certified. This programme is now over-
seen by the International Society for the Study of Pleura
and Peritoneum92. In addition, clinicians were asked to
agree to submit data from all cases to an international reg-
istry, managed independently by the University of Magde-
burg (NCT03210298).
Stage 2b – Exploration: expanding the indications
As experience of PIPAC has increased, there has been evo-
lution in the perioperative management of these patients,
and in the indications for surgery. The duration of hospi-
tal stay has decreased, and in one centre selected patients
undergo PIPAC as a day-case procedure75. Additional tech-
nology has been applied to the technique by some users.
Electrostatic PIPAC (ePIPAC) involves the application of
electrostatic precipitation to the abdominal cavity, with the
aim of increasing drug deposition and adsorption. In pre-
clinical testing, its use during PIPAC increased the pen-
etration of drug17. The use of PIPAC in other scenarios,
for example in combination with systemic chemotherapy,
is under investigation57,86. Although the majority of pro-
cedures are still performed where disease has progressed
despite conventional treatment, one centre87 has proposed
a randomized trial that will use PIPAC as adjuvant therapy
after resection of high-risk colorectal cancer. The potential
of PIPAC as a downstaging treatment to enable cytoreduc-
tive surgery was noted in some of the larger retrospective
case series82,93, and will be evaluated further in an upcom-
ing RCT86.
The future: Moving to stage 3
As documented in Fig. 2, there has been rapid expansion
in the published literature since the first human report of
PIPAC less than a decade ago, and an increasing number
of centres are participating. PIPAC is now in widespread
use worldwide. There are a number of RCTs proposed
or ongoing86,89–91, focusing in particular on survival and
aiming to determine whether PIPAC could become part of
standard care in the treatment of peritoneal disease.
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Discussion
The introduction of PIPAC has, in principle, followed the
pattern of investigation advocated by the IDEAL collabo-
ration. However, this review of the development of PIPAC
has highlighted some of the difficulties in research in sur-
gical practice. Despite hundreds of reported cases in the
literature, the true efficacy of the procedure is still unclear.
In many instances, PIPAC has been initiated outside
of a trial. Although centres have published case series
of prospectively collected data, there have been multiple
publications of data from overlapping time periods, for
example in 2014 and 201513,38,55,74 and 201640,73. Formally
registered programmes of research have also been con-
ducted, usually consisting of small studies of safety and
feasibility initially, followed by larger cohort studies. How-
ever, this pattern has been repeated several times across
different centres in different countries. This may have been
unnecessary in cases where the same drug doses and proce-
dural steps were used, and may have delayed the progres-
sion to larger phase II/III studies.
The difficulty of overcoming the technical learning curve
associated with a new procedure has been described as
a potential barrier to effective research in surgery in the
past3,4. In the case of PIPAC, there may also be issues
relating to patient selection and perioperative care. Other
reasons for the duplication of safety studies may relate to
individual regulatory requirements in the different coun-
tries, or because studies were conceived before the results
of earlier trials had been published.
The IDEAL framework recommends that trial proto-
cols are registered publicly, and advocates the reporting of
the results from new procedures on online registers avail-
able to all surgeons2. This recommendation has not been
followed by all PIPAC centres. Although 67 clinical stud-
ies were published, only 23 of them were registered on
ClinicalTrials.gov and EudraCT.
There is also the issue of the limited funds available
for surgical studies. This can result in the duplication of
smaller, less powerful, studies, without assessing the effect
of the treatment on longer-term outcomes.
Ethical concerns have been raised in the past about
surgical innovation94. Three systematic reviews95–97 have
summarized the likelihood of adverse effects after PIPAC,
although the lack of efficacy data resulting from controlled
trials makes a risk versus benefit discussion challenging.
There may also be rare complications not identified
during early development of the technique, such as the
cases of peritoneal sclerosis after PIPAC with oxaliplatin65
and severe hypersensitivity reactions to platinum-based
chemotherapy during PIPAC69. The IDEAL Collabo-
ration suggest that clinicians use all available data from
previous studies to counsel patients and disclose the
possibility of unknown or unanticipated side-effects and
complications5.
There may be ethical concerns relating to the involve-
ment of the innovator or manufacturer of a new device in
ongoing research. In the case of PIPAC, the sale of the
MicroPump™/CapnoPen® device was initially limited to
clinicians who had been trained by the developer, and a
contribution to an independently managed international
registry (NCT03210298) was expected. An annual sympo-
sium was organized, and latterly this platform for sharing
experience and update training has been formalized with
the foundation of the International Society for the Study of
Pleura and Peritoneum92, contributing to standardization
of the technique98. This may prove useful for the conduct
of multicentre trials in the future.
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